TABLE 3.

Summary of randomised controlled trials with anti-interleukin-5 treatment: eosinophil threshold used in each trial and percentage of atopics in enrolled patients

First author [ref.]	Year	Treatment	Eosinophil threshold	Patients n	Atopic
Haldar [24]	2009	Mepolizumab	>3% sputum eosinophils	61	68% SPT+
Castro [54]	2011	Reslizumab	>3% sputum eosinophils	106	80% allergic rhinitis
Pavord [15]	2012	Mepolizumab	>300 μL−1 blood eosinophils	616	50% SPT+
Ortega [55]	2014	Mepolizumab	>150 μL−1 blood eosinophils at screening or >300 μL−1 during previous year	576	49% allergic rhinitis
Bel [56]	2014	Mepolizumab	>300 μL−1 blood eosinophils	135	46% allergic rhinitis
Castro [58]	2014	Benralizumab	No threshold for eosinophils; FENO >50 ppb used as surrogate marker	244	Not reported
Castro [57]	2015	Reslizumab	>400 μL−1 blood eosinophils	953	Not reported
Corren [66]	2016	Reslizumab	No initial threshold for eosinophils; ≥400 μL−1 blood eosinophils as clinically significant	492	Not reported
Bjermer [65]	2016	Reslizumab	≥400 μL−1 blood eosinophils	315	Not reported
FitzGerald [60]	2016	Benralizumab	No initial threshold for eosinophils; ≥300 μL−1 blood eosinophils as clinically significant	1306	62% RAST+
Bleecker [59]	2016	Benralizumab	No initial threshold for eosinophils; ≥300 μL−1 blood eosinophils as clinically significant	1204	63% RAST+

SPT: skin prick test; F_ENO: exhaled nitric oxide fraction; RAST: radioallergosorbent test.